https://www.selleckchem.com/products/eed226.html
Transdiagnostic prevention and management intervention strategies could be explored. We previously described a risk prediction model (Anne Arundel Medical Center [AAMC] model) based on pathology which may eliminate the need for recurrence score (RS) testing in select early-stage breast cancers. There is a concern that patients in discordant risk prediction groups (AAMC vs. RS) may be overtreated or undertreated if RS testing were omitted. We queried the Surveillance, Epidemiology, and End Results (SEER) database for all breast cancer pat
Suka
Komentar
Membagikan
